TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17446339

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 14998802

Group type: EXPERIMENTAL
Intervention: Group-randomized trials (GRTs)
Number of subjects: 60
Study: 11437017

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 173

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 173
Study: 9709756

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% (Voltaren)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Prednisolone sodium phosphate 1% ophthalmic solution
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both diclofenac and prednisolone
Number of subjects: 52
Study: 7977070

Group type: EXPERIMENTAL
Intervention: Sotalol (240 mg twice daily for 7 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg 3 times daily for 10 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sotalol and Amiodarone
Number of subjects: 34
Study: 2535309

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF), 100 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nitroglycerin, 200 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside, 120 micrograms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Phentolamine, 3 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 54209

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 60

Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 60
Study: 31585978

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balance and Tone (Control)
Number of subjects: 20
Study: 28009728

Group type: EXPERIMENTAL
Intervention: FOREseal (alginate staple‐line reinforcement)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control (standard management)
Number of subjects: 380
Study: 26508645

Group type: EXPERIMENTAL
Intervention: Breast augmentation in the subglandular plane
Number of subjects: 34

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 34
Study: 23128283

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led telephone support (n = 187)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Usual care (n = 194)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring with nurse-led telephone support
Number of subjects: 381
Study: 21562712

Group type: EXPERIMENTAL
Intervention: Weight lifting intervention for 12 months
Number of subjects: 295
Study: 19373930

Group type: EXPERIMENTAL
Intervention: Sensory attention focused exercise (PD SAFEx)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lower-limb aerobic training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 46
Study: 17351806

Group type: EXPERIMENTAL
Intervention: Ulinastatin (150,000 units)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gabexate mesylate (600 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gabexate mesylate
Number of subjects: 68
Study: 12605430

Group type: EXPERIMENTAL
Intervention: Intra-operative Photofrin-photodynamic therapy (PDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging system performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photofrin-PDT
Number of subjects: 0
Study: 10702454

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg morphine
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg morphine
Number of subjects: 245
Study: 9356793

Group type: EXPERIMENTAL
Intervention: Adjuvant selective decontamination (SD)
Number of subjects: 102
Study: 8447205

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with epinephrine, 20 ml, intermittent 8-hourly bolus injections
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2943816

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (HBX‐R) administered IM at 10 micrograms, 3 doses (0, 1 month, 6 months)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Plasma-derived hepatitis B vaccine (H‐B‐VAX) administered IM at 20 micrograms, 3 doses (0, 1 month, 6 months)
Number of subjects: 199
Study: 31560577

Group type: EXPERIMENTAL
Intervention: Sports medicine physicians
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Family/internal medicine physicians
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Pediatricians
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: General physicians
Number of subjects: 4500
Study: 29446377

Group type: EXPERIMENTAL
Intervention: Tiotropium bromide inhalation powder combined with fluticasone propionate aerosol (group D)
Number of subjects: 160
Study: 27431995

Group type: EXPERIMENTAL
Intervention: Daily trimethoprim-sulfamethoxazole (TS) prophylaxis
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Weekly chloroquine (CQ) prophylaxis
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Discontinuation of standard of care TS prophylaxis
Number of subjects: 1400
Study: 24615137

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Artesunate (AS) in combination with sulfadoxine/pyrimethamine (SP)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Artesunate (AS) and dihydroartemisinin (DHA)
Number of subjects: 16
Study: 22537281

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention for 5 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 150
Study: 20451689

Group type: EXPERIMENTAL
Intervention: RVAP (n = 28)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: RVSP (n = 32)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (n = 21)
Number of subjects: 93
Study: 18547983

Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF) after surgical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro fertilization (IVF) offered sooner to older patients or those with more severe disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical removal of endometriomas
Number of subjects: 0
Study: 16287402

Group type: EXPERIMENTAL
Intervention: Food, Mood, and Attitude (FMA) intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study: 12573690

Group type: EXPERIMENTAL
Intervention: Day treatment
Number of subjects: 79

Group type: COMPARATOR
Intervention: Outpatient addiction counseling
Number of subjects: 79
Study: 10389026

Group type: EXPERIMENTAL
Intervention: B-vitamins (400 micrograms folic acid + 1.65 mg pyridoxine + 3 micrograms cyanocobalamin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9060347

Group type: EXPERIMENTAL
Intervention: Experimental group (time in situ ≤ 24 hours)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (current/daily routines)
Number of subjects: 120
Study: 1650406

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Low-molecular-weight heparin and Unfractionated heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin and Unfractionated heparin
Number of subjects: 0
Study: 7104806

Group type: EXPERIMENTAL
Intervention: 4 mg epidural morphine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 8 mg epidural morphine
Number of subjects: 3

Group type: COMPARATOR
Intervention: 0 mg (saline control)
Number of subjects: 3
Study: 30915471

Group type: EXPERIMENTAL
Intervention: PA + green-MED diet
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: FG14
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Mankai 50
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Mankai 80
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: FG9.5
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Mankai 50-C
Number of subjects: 294

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 294
Study: 29309599

Group type: EXPERIMENTAL
Intervention: Scheduled Gradual Reduction (SGR) program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (non-SGR text messaging support)
Number of subjects: 40
Study: 27409799

Group type: EXPERIMENTAL
Intervention: CHX solution with SRP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CHX gel with SRP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CHX chip with SRP
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control SRP
Number of subjects: 120
Study: 25544509

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Naftopidil 75 mg
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study: 22929677

Group type: EXPERIMENTAL
Intervention: Detralex (1,000 mg daily for 2 weeks prior and 4 weeks after endovascular treatment)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional compression therapy (compression bandages or medicinal knitted fabric)
Number of subjects: 230
Study: 20674884

Group type: EXPERIMENTAL
Intervention: Music presented in a major (happy) key
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Music presented in a minor (sad) key
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sine wave control music
Number of subjects: 0
Study: 17272737

Group type: EXPERIMENTAL
Intervention: Enhanced written consent procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slideshow presentation
Number of subjects: 0
Study: 15663066

Group type: EXPERIMENTAL
Intervention: Message campaign about hand hygiene and availability of gel hand sanitizer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 12858132

Group type: EXPERIMENTAL
Intervention: Topiramate (initial dose of 25 mg/day to a target dose of 100 mg BID)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10235193

Group type: EXPERIMENTAL
Intervention: Garlic (10 sliced cloves)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Capsaicin (6 sliced fresh jalapeños)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bismuth subsalicylate (2 tablets of Pepto-Bismol, positive control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nothing added (negative control)
Number of subjects: 12
Study: 9074893

Group type: EXPERIMENTAL
Intervention: Paracetamol tablets (two lots)
Number of subjects: 5
Study: 1751620

Group type: EXPERIMENTAL
Intervention: MCPP (0.25 mg/kg)
Number of subjects: 7
Study: 7047172

Group type: EXPERIMENTAL
Intervention: Metergoline 4 mg tid for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg bid for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metergoline (continued treatment for 7 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bromocriptine (continued treatment for 7 days)
Number of subjects: 40
Study: 31017513

Group type: EXPERIMENTAL
Intervention: Marker-based RSA
Number of subjects: 57

Group type: COMPARATOR
Intervention: Model-based RSA
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Polyethylene insert micromotion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall migration data pooling
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Translations
Number of subjects: 57
Study: 28285644

Group type: EXPERIMENTAL
Intervention: 5g transdermal testosterone gel (TT) daily for 12 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1mg oral aromatase inhibitor (AI) daily for 12 months
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 25231884

Group type: EXPERIMENTAL
Intervention: Culturally tailored, theory‐based nutrition education workshops focusing on dietary fat and brain health
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Culturally tailored, theory‐based nutrition education workshops focusing only on dietary fat and heart health
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posttest only control group
Number of subjects: 0
Study: 24438121

Group type: EXPERIMENTAL
Intervention: CBTX‐A (Chinese type A botulinum toxin)
Number of subjects: 20

Group type: COMPARATOR
Intervention: onabotulinumtoxinA
Number of subjects: 20
Study: 21993890

Group type: EXPERIMENTAL
Intervention: High sodium intake (300 mmol sodium/day; 17.5 g salt/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low sodium intake (30 mmol sodium/day; 1.8 g salt/day)
Number of subjects: 21
Study: 19142669

Group type: EXPERIMENTAL
Intervention: Lidocaine patches
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 28
Study: 17298413

Group type: EXPERIMENTAL
Intervention: 4-hour lecture on root canal instrumentation
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 4-hour lecture + 6-hour hands-on training
Number of subjects: 148
Study: 11145439

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) induction treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon (IFN) maintenance treatment
Number of subjects: 30
Study: 8967887

Group type: EXPERIMENTAL
Intervention: Fallback I algorithm (Chorus I, Ela Medical Inc.)
Number of subjects: 45
Study: 1360698

Group type: EXPERIMENTAL
Intervention: Rehearsal group (imagery rehearsal technique)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recording group (no other intervention)
Number of subjects: 20
Study: 2857610

Group type: EXPERIMENTAL
Intervention: Guanfacine (alpha 2‐agonist)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Idazoxan (alpha 2‐antagonist)
Number of subjects: 6
Study: 30398039

Group type: EXPERIMENTAL
Intervention: Lifestyle modification group
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Metformin group
Number of subjects: 744

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 744
Study: 29405359

Group type: EXPERIMENTAL
Intervention: Consecutive very-low-calorie diet (2 consecutive days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-consecutive very-low-calorie diet (2 non-consecutive days)
Number of subjects: 41
Study: 27357800

Group type: EXPERIMENTAL
Intervention: Lower body heating (LBH)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Unilateral thigh heating (TH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 24450471

Group type: EXPERIMENTAL
Intervention: Peanut enriched ADA meal plan (20% of energy from peanuts)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peanut-free ADA meal plan (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Weight loss in entire cohort
Number of subjects: 60
Study: 22950522

Group type: COMPARATOR
Intervention: GLPG0259 single ascending doses (1.5-150 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GLPG0259 multiple doses (20 and 50 mg once daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GLPG0259 multiple doses (25-75 mg once daily for 14 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GLPG0259 solid dosage form
Number of subjects: 70

Group type: COMPARATOR
Intervention: GLPG0259
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20021522

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 151

Group type: COMPARATOR
Intervention: Quarterly device interrogations in clinic (Control)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control (Quarterly device interrogations in clinic)
Number of subjects: 151
Study: 17511187

Group type: EXPERIMENTAL
Intervention: Intermittent epidural fentanyl
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent intravenous pethidine
Number of subjects: 50
Study: 16139629

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11941270

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 709

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study: 10513040

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine in treating coronary artery disease (CAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management of conventional and emerging risk factors for CVD in high-risk individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-center and multinational randomized and epidemiological studies
Number of subjects: 0
Study: 8822437

Group type: EXPERIMENTAL
Intervention: Sperm deposition at 6 o'clock position
Number of subjects: 6860

Group type: COMPARATOR
Intervention: Sperm deposition at 12 o'clock position
Number of subjects: 6860

Group type: EXPERIMENTAL
Intervention: Membrane breakage type A
Number of subjects: 6860

Group type: EXPERIMENTAL
Intervention: Membrane breakage type B
Number of subjects: 6860

Group type: EXPERIMENTAL
Intervention: Membrane breakage type C
Number of subjects: 6860

Group type: EXPERIMENTAL
Intervention: Membrane breakage type D
Number of subjects: 6860

Group type: EXPERIMENTAL
Intervention: Membrane breakage type E
Number of subjects: 6860
Study: 2126726

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soluble aspirin 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin and glycine formulation 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin doses above 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release aspirin doses of 50 mg and below
Number of subjects: 0
Study: 30865629

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS) given to mothers and children during the first 1,000 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 27919901

Group type: EXPERIMENTAL
Intervention: CD101 IV 50 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CD101 IV 100 mg (once weekly for 2 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CD101 IV 200 mg (once weekly for 2 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CD101 IV 400 mg (once weekly for 3 weeks)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 25145377

Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg single dose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23743101

Group type: EXPERIMENTAL
Intervention: Wearable low-intensity therapeutic ultrasound (LITUS) device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 30
Study: 21808760

Group type: EXPERIMENTAL
Intervention: TiOblast™ (Astra Tech) implants
Number of subjects: 18

Group type: COMPARATOR
Intervention: Brånemark (Nobel Biocare) implants
Number of subjects: 18

Group type: COMPARATOR
Intervention: Natural dentition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 18
Study: 20098348

Group type: EXPERIMENTAL
Intervention: EECP + traction
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: EECP
Number of subjects: 163

Group type: COMPARATOR
Intervention: Traction
Number of subjects: 163
Study: 17685740

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT-imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBT-paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study: 16366040

Group type: EXPERIMENTAL
Intervention: Test product (Vimpocetina)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 24
Study: 11934971

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) 2% ointment applied for 1 minute
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo ointment applied for 1 minute
Number of subjects: 33

Group type: COMPARATOR
Intervention: No treatment (untreated finger)
Number of subjects: 33
Study: 9469350

Group type: EXPERIMENTAL
Intervention: I.V.‐oral regimen
Number of subjects: 12

Group type: COMPARATOR
Intervention: I.V. mesna regimen
Number of subjects: 12
Study: 7612061

Group type: EXPERIMENTAL
Intervention: 4 x 150 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 4 x 300 mg ranitidine + 4 x 500 mg amoxicillin for 2 weeks, followed by 300 mg ranitidine for 2 weeks
Number of subjects: 196
Study: 2242456

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily (increased to a maximum of 200 micrograms daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 38176

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 569

Group type: COMPARATOR
Intervention: None of the drugs
Number of subjects: 569
Study: 30954442

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 28220604

Group type: EXPERIMENTAL
Intervention: mHealth intervention promoting healthy diet, physical activity and gestational weight gain
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 26287417

Group type: EXPERIMENTAL
Intervention: PPB‐R‐203
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84